Hair Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major hair diseases markets reached a value of US$ 6.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 11.6 Billion by 2034, exhibiting a growth rate (CAGR) of 6.05% during 2024-2034.
The hair diseases market has been comprehensively analyzed in IMARC's new report titled "Hair Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hair diseases refer to a variety of conditions that affect the scalp and hair follicles, resulting in abnormalities in hair growth, structure, or appearance. These disorders can lead to hair loss, scalp discomfort, and cosmetic concerns. The illnesses are commonly characterized by gradual hair thinning and receding hairlines. Some common symptoms include small, pus-filled bumps or sores on the scalp, bald patches, scaling, flaking, itchiness, inflammation, redness, excessive oiliness or dryness, breakage and brittleness, scalp tenderness or pain, the development of fine, wispy hairs, etc. In a few cases, individuals suffering from the disorders may also experience changes in hair color, such as graying or whitening. The diagnosis of the conditions is mainly based on a comprehensive review of the patient's medical history, clinical features, and physical exam. Additionally, a trichoscopy, which uses a handheld device called a dermatoscope, is recommended to visualize structural and color changes in the hair shaft as well as determine the presence of scaling, broken hairs, or other abnormalities. The healthcare provider may further perform a scalp biopsy to confirm the diagnosis.
The increasing prevalence of various associated risk factors, such as stress, traumatic events, hormonal changes, certain medications, etc., that cause a disruption in the hair growth cycle is primarily driving the hair diseases market. In addition to this, the rising incidence of autoimmune disorders, in which the body's defense system mistakenly attacks the hair follicles, resulting in patchy or widespread hair loss, is creating a positive outlook for the market. Moreover, the inflating application of platelet-rich plasma therapy, since it involves injecting concentrated platelets derived from the patient's blood into the scalp to enhance the appearance of hair, is further bolstering the market growth. Apart from this, the escalating adoption of 5-alpha reductase inhibitors, which help to inhibit the conversion of testosterone to dihydrotestosterone, thereby preventing baldness, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of low-level laser devices to treat ailments by enhancing blood circulation and promoting a healthier scalp environment for hair follicles is expected to drive the market during the hair diseases forecast period.
IMARC Group's new report provides an exhaustive analysis of the hair diseases market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hair diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hair diseases market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hair diseases market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hair diseases market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hair diseases marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the hair diseases market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hair diseases market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hair diseases market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of hair diseases across the seven major markets?
What is the number of prevalent cases (2018-2034) of hair diseases by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hair diseases by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with hair diseases across the seven major markets?
What is the size of the hair diseases patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hair diseases?
What will be the growth rate of patients across the seven major markets?
Hair Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hair diseases drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hair diseases market?
What are the key regulatory events related to the hair diseases market?
What is the structure of clinical trial landscape by status related to the hair diseases market?
What is the structure of clinical trial landscape by phase related to the hair diseases market?
What is the structure of clinical trial landscape by route of administration related to the hair diseases market?
The hair diseases market has been comprehensively analyzed in IMARC's new report titled "Hair Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hair diseases refer to a variety of conditions that affect the scalp and hair follicles, resulting in abnormalities in hair growth, structure, or appearance. These disorders can lead to hair loss, scalp discomfort, and cosmetic concerns. The illnesses are commonly characterized by gradual hair thinning and receding hairlines. Some common symptoms include small, pus-filled bumps or sores on the scalp, bald patches, scaling, flaking, itchiness, inflammation, redness, excessive oiliness or dryness, breakage and brittleness, scalp tenderness or pain, the development of fine, wispy hairs, etc. In a few cases, individuals suffering from the disorders may also experience changes in hair color, such as graying or whitening. The diagnosis of the conditions is mainly based on a comprehensive review of the patient's medical history, clinical features, and physical exam. Additionally, a trichoscopy, which uses a handheld device called a dermatoscope, is recommended to visualize structural and color changes in the hair shaft as well as determine the presence of scaling, broken hairs, or other abnormalities. The healthcare provider may further perform a scalp biopsy to confirm the diagnosis.
The increasing prevalence of various associated risk factors, such as stress, traumatic events, hormonal changes, certain medications, etc., that cause a disruption in the hair growth cycle is primarily driving the hair diseases market. In addition to this, the rising incidence of autoimmune disorders, in which the body's defense system mistakenly attacks the hair follicles, resulting in patchy or widespread hair loss, is creating a positive outlook for the market. Moreover, the inflating application of platelet-rich plasma therapy, since it involves injecting concentrated platelets derived from the patient's blood into the scalp to enhance the appearance of hair, is further bolstering the market growth. Apart from this, the escalating adoption of 5-alpha reductase inhibitors, which help to inhibit the conversion of testosterone to dihydrotestosterone, thereby preventing baldness, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of low-level laser devices to treat ailments by enhancing blood circulation and promoting a healthier scalp environment for hair follicles is expected to drive the market during the hair diseases forecast period.
IMARC Group's new report provides an exhaustive analysis of the hair diseases market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hair diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hair diseases market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hair diseases market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hair diseases market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hair diseases marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the hair diseases market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hair diseases market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hair diseases market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of hair diseases across the seven major markets?
What is the number of prevalent cases (2018-2034) of hair diseases by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hair diseases by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with hair diseases across the seven major markets?
What is the size of the hair diseases patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hair diseases?
What will be the growth rate of patients across the seven major markets?
Hair Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hair diseases drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hair diseases market?
What are the key regulatory events related to the hair diseases market?
What is the structure of clinical trial landscape by status related to the hair diseases market?
What is the structure of clinical trial landscape by phase related to the hair diseases market?
What is the structure of clinical trial landscape by route of administration related to the hair diseases market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HAIR DISEASES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HAIR DISEASES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HAIR DISEASES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 HAIR DISEASES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HAIR DISEASES - UNMET NEEDS
10 HAIR DISEASES - KEY ENDPOINTS OF TREATMENT
11 HAIR DISEASES - MARKETED PRODUCTS
11.1 List of Hair Diseases Marketed Drugs Across the Top 7 Markets
11.1.1 Olumiant (Baricitinib) - Eli Lilly and Company/Incyte Corporation
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Litfulo (Ritlecitinib) - Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HAIR DISEASES - PIPELINE DRUGS
12.1 List of Hair Diseases Pipeline Drugs Across the Top 7 Markets
12.1.1 FOL 005 - Follicum AB
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Etrasimod - Pfizer
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 CTP 543 - Concert Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 TDM105795 - TechnoDerma Medicines
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HAIR DISEASES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HAIR DISEASES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HAIR DISEASES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hair Diseases - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hair Diseases - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hair Diseases - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hair Diseases - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hair Diseases - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hair Diseases - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hair Diseases - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hair Diseases - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hair Diseases - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hair Diseases - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hair Diseases - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hair Diseases - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hair Diseases - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hair Diseases - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hair Diseases - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hair Diseases - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hair Diseases - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hair Diseases - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hair Diseases - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hair Diseases - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hair Diseases - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hair Diseases - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hair Diseases - Access and Reimbursement Overview
16 HAIR DISEASES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HAIR DISEASES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HAIR DISEASES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HAIR DISEASES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HAIR DISEASES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HAIR DISEASES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 HAIR DISEASES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HAIR DISEASES - UNMET NEEDS
10 HAIR DISEASES - KEY ENDPOINTS OF TREATMENT
11 HAIR DISEASES - MARKETED PRODUCTS
11.1 List of Hair Diseases Marketed Drugs Across the Top 7 Markets
11.1.1 Olumiant (Baricitinib) - Eli Lilly and Company/Incyte Corporation
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Litfulo (Ritlecitinib) - Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HAIR DISEASES - PIPELINE DRUGS
12.1 List of Hair Diseases Pipeline Drugs Across the Top 7 Markets
12.1.1 FOL 005 - Follicum AB
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Etrasimod - Pfizer
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 CTP 543 - Concert Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 TDM105795 - TechnoDerma Medicines
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HAIR DISEASES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HAIR DISEASES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HAIR DISEASES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hair Diseases - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hair Diseases - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hair Diseases - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hair Diseases - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hair Diseases - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hair Diseases - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hair Diseases - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hair Diseases - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hair Diseases - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hair Diseases - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hair Diseases - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hair Diseases - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hair Diseases - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hair Diseases - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hair Diseases - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hair Diseases - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hair Diseases - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hair Diseases - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hair Diseases - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hair Diseases - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hair Diseases - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hair Diseases - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hair Diseases - Access and Reimbursement Overview
16 HAIR DISEASES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HAIR DISEASES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HAIR DISEASES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
